| Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights |
Last Wednesday, NeuroSense Therapeutics Ltd. NRSN said it scaled up its production of PrimeC to a commercial scale. |
benzinga.com |
2025-05-12 19:08:07 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch |
NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass. , May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2025-05-07 12:45:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update |
Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company CAMBRIDGE, Mass. , April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2025-04-24 13:09:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment |
New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS. CAMBRIDGE, Mass. |
prnewswire.com |
2025-04-09 12:30:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates |
Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization Phase 3 study design for PrimeC in ALS aligned with FDA; planned initiation in 2025 CAMBRIDGE, Mass. , April 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2025-04-07 21:14:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting |
Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense CAMBRIDGE, Mass. , April 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. |
prnewswire.com |
2025-04-04 13:10:00 |
Czytaj oryginał (ang.) |
| Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug |
NEW YORK--(BUSINESS WIRE)--Market News Alerts Reports: NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited the company to a pre-New Drug Submission (pre-NDS) meeting to discuss a potential Notice of Compliance/conditional (NOC/c) regulatory pathway for PrimeC as a treatment for Amyotrophic Lateral Sclerosis (ALS). NeuroSense is ta. |
businesswire.com |
2025-03-20 12:30:00 |
Czytaj oryginał (ang.) |
| PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape |
NEW YORK--(BUSINESS WIRE)---- $NRSN #ALS--PESG Research releases a new report covering NeuroSense Therapeutics (NASDAQ: NRSN)* and its recent developments: In a medical landscape hungry for innovation, NeuroSense Therapeutics (NASDAQ: NRSN) stands at the forefront of a potential revolution in ALS treatment, developing a groundbreaking combination therapy that could fundamentally transform the approach to one of the most devastating neurological disorders. With clinical data showing a remarkable 36% reduction. |
businesswire.com |
2025-03-17 10:30:00 |
Czytaj oryginał (ang.) |
| NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement |
NeuroSense in Compliance with all Nasdaq Listing Requirements CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2025-01-06 11:00:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS |
Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additionally, milestone payments and double-digit royalties on annual net sales The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025 CAMBRIDGE, Mass. , Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-12-23 11:00:00 |
Czytaj oryginał (ang.) |
| NeuroSense Provides Business Update and Third Quarter 2024 Financial Results |
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-12-18 12:25:00 |
Czytaj oryginał (ang.) |
| NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC |
The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS CAMBRIDGE, Mass. , Dec. 11, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-12-11 11:25:00 |
Czytaj oryginał (ang.) |
| NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS |
In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), demonstrated in a 58% improvement in survival rates Consistent data across subgroups underscore the potential of PrimeC to redefine the standard of care in the treatment of ALS CAMBRIDGE, Mass. , Dec. 4, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-12-04 10:30:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price |
CAMBRIDGE, Mass. , Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-12-02 10:30:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND |
CAMBRIDGE, Mass. , Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-11-21 11:20:00 |
Czytaj oryginał (ang.) |
| NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission |
Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by Q1 2026 CAMBRIDGE, Mass. , Oct. 28, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-10-28 10:30:00 |
Czytaj oryginał (ang.) |
| New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients |
Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE, Mass. , Oct. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-10-24 12:30:00 |
Czytaj oryginał (ang.) |
| NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates |
Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval efforts to additional global markets CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-10-15 13:15:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada |
The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves survival rates by 43% Company plans to seek approval in additional countries CAMBRIDGE, Mass. , Oct. 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-10-09 13:00:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting |
CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-10-07 13:00:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's |
The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-09-24 13:05:00 |
Czytaj oryginał (ang.) |
| NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule |
CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-09-24 13:00:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification |
CAMBRIDGE, Mass. , Aug. 30, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-08-30 20:30:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price |
CAMBRIDGE, Mass. , Aug. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-08-07 18:00:00 |
Czytaj oryginał (ang.) |
| NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial |
12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous results showed PrimeC slowed disease progression by 36% and improved survival rates, highlighting its potential as a transformative ALS therapy CAMBRIDGE, Mass. , Aug. 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-08-01 13:15:00 |
Czytaj oryginał (ang.) |
| NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression |
NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. , July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-07-09 13:27:00 |
Czytaj oryginał (ang.) |
| This cheap biotech offers investors a play on ALS if trial data continues to impress |
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS. |
marketwatch.com |
2024-07-02 16:34:00 |
Czytaj oryginał (ang.) |
| NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug |
Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placebo Consistent data across multiple endpoints underscore the potential of PrimeC to redefine the ALS treatment paradigm NeuroSense planning for Phase 3 clinical study in the U.S. and Europe CAMBRIDGE, Mass. , July 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-07-01 12:00:00 |
Czytaj oryginał (ang.) |
| NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results |
Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. |
prnewswire.com |
2024-06-24 13:00:00 |
Czytaj oryginał (ang.) |